Literature DB >> 27956008

Effect of bumetanide, a selective NKCC1 inhibitor, on hallucinations of schizophrenic patients; a double-blind randomized clinical trial.

Reza Rahmanzadeh1, Sanaz Eftekhari2, Ali Shahbazi2, Mohammad-Reza Khodaei Ardakani3, Ramin Rahmanzade1, Soraya Mehrabi1, Mahmood Barati1, Mohammad Taghi Joghataei4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27956008     DOI： 10.1016/j.schres.2016.12.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN： 0920-9964            Impact factor:   4.939


× No keyword cloud information.
  10 in total

1.  Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.

Authors:  Hon-Cheong So; Carlos Kwan-Long Chau; Wan-To Chiu; Kin-Sang Ho; Cho-Pong Lo; Stephanie Ho-Yue Yim; Pak-Chung Sham
Journal:  Nat Neurosci       Date:  2017-08-14       Impact factor: 24.884

Review 2.  Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: an update on pharmacological and enzyme-replacement therapeutic strategies.

Authors:  Kara R Vogel; Garrett R Ainslie; Dana C Walters; Alice McConnell; Sameer C Dhamne; Alexander Rotenberg; Jean-Baptiste Roullet; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2018-02-19       Impact factor: 4.982

Review 3.  Off-Label Use of Bumetanide for Brain Disorders: An Overview.

Authors:  Shivani C Kharod; Seok Kyu Kang; Shilpa D Kadam
Journal:  Front Neurosci       Date:  2019-04-24       Impact factor: 4.677

4.  Get With the (Developmental) Program.

Authors:  Jamie L Maguire
Journal:  Epilepsy Curr       Date:  2020-03-23       Impact factor: 7.500

Review 5.  Targeting the WNK-SPAK/OSR1 Pathway and Cation-Chloride Cotransporters for the Therapy of Stroke.

Authors:  Sunday Solomon Josiah; Nur Farah Meor Azlan; Jinwei Zhang
Journal:  Int J Mol Sci       Date:  2021-01-27       Impact factor: 5.923

6.  Depolarizing GABAA current in the prefrontal cortex is linked with cognitive impairment in a mouse model relevant for schizophrenia.

Authors:  Haram R Kim; Lakshmi Rajagopal; Herbert Y Meltzer; Marco Martina
Journal:  Sci Adv       Date:  2021-03-31       Impact factor: 14.136

7.  Analgesic Effect of Bumetanide on Neuropathic Pain in Patients With Spinal Cord Injury.

Authors:  Farinaz Nasirinezhad; Leila Zarepour; Mahmoudreza Hadjighassem; Zeinab Gharaylou; Hossin Majedi; Fatemeh Ramezani
Journal:  Basic Clin Neurosci       Date:  2021-05-01

8.  Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders.

Authors:  Annalisa Savardi; Marco Borgogno; Roberto Narducci; Giuseppina La Sala; Jose Antonio Ortega; Maria Summa; Andrea Armirotti; Rosalia Bertorelli; Andrea Contestabile; Marco De Vivo; Laura Cancedda
Journal:  Chem       Date:  2020-08-06       Impact factor: 22.804

Review 9.  Developmental Genes and Regulatory Proteins, Domains of Cognitive Impairment in Schizophrenia Spectrum Psychosis and Implications for Antipsychotic Drug Discovery: The Example of Dysbindin-1 Isoforms and Beyond.

Authors:  John L Waddington; Xuechu Zhen; Colm M P O'Tuathaigh
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

Review 10.  Physiological Processes Modulated by the Chloride-Sensitive WNK-SPAK/OSR1 Kinase Signaling Pathway and the Cation-Coupled Chloride Cotransporters.

Authors:  Adrián Rafael Murillo-de-Ozores; María Chávez-Canales; Paola de Los Heros; Gerardo Gamba; María Castañeda-Bueno
Journal:  Front Physiol       Date:  2020-10-20       Impact factor: 4.566
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.